Nuvation Bio is a pre-profitability biotech with a 26% short interest and put/call ratio of 9.0, but analysts project more than 140% upside and the company maintains a strong current ratio, leaving the risk-reward asymmetric and highly speculative.
Thesis pillars
- Analyst Upside Vs Short Pressure→Stable
- Cash Position And Current Ratio→Stable
- Obv Accumulation Recovery Setup→Stable
- +1 more pillar — see the Why tab for full reasoning
Nuvation Bio Inc. (NUVB) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.77: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality.
Nuvation Bio is a global oncology company that commercially launched IBTROZI (taletrectinib), a ROS1 inhibitor for metastatic non-small cell lung cancer, in the U.S. in June 2025 following FDA approval, with taletrectinib also approved in Japan (marketed by partner Nippon... Read more
Sell if holding. Engine safety override at $5.77: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-06Recent Developments — Nuvation Bio Inc.
Latest news
- NEWS UK's MHRA Validated Marketing Authorization Application Submitted By Nuvation Bio's Partner, Eisai, For Taletrectinib Fo — benzinga Jun 29, 2026 positive
- NEWS Reported Earlier, Nuvation Bio Prices Upsized $250M Offering Of 0.75% Convertible Senior Notes Due 2032 — benzinga Jun 26, 2026 positive
- NEWS H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session — benzinga Jun 25, 2026 neutral
- NEWS Nuvation Bio Intends To Offer $200M Aggregate Principal Amount Of Convertible Senior Notes Due In 2032 — benzinga Jun 25, 2026 negative
- NEWS Nuvation Bio To Showcase New Outcomes Data From Its Pivotal TRUST-II Trial Of IBTROZI In Participants With Advanced ROS1 — benzinga May 27, 2026 positive
Generated 2026-07-06T05:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductIBTROZI (taletrectinib)10-K Item 1A: 'IBTROZI is our only product approved for marketing by the FDA, and our ability to generate revenue from product sales and achieve profitability is mostly dependent on our ability'
- HIGHcounterpartyDaiichi Sankyo (in-license partner)10-K Item 1: 'Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), pursuant to which Daiichi Sankyo granted to AHT exclusive worldwide rights to develop and commercialize taletrectinib'
Material Events(8-K, last 90d)
- 2026-06-30Item 1.01LOWNuvation Bio completed a $250.0 million offering of 0.75% Convertible Senior Notes due 2032 and amended its Revenue Interest Financing Agreement with Sagard Healthcare Partners in connection with the offering; a routine capital-raise and financing amendment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Volatile — 7.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.77: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $5.30. Score 5.0/10, moderate confidence.
Take-profit target: $10.73 (+88.2% upside). Prior stop was $5.30. Stop-loss: $5.30.
Concentration risk — Product: IBTROZI (taletrectinib); Concentration risk — Counterparty: Daiichi Sankyo (in-license partner); Risk below floor (2.8 < 3.0).
Nuvation Bio Inc. trades at a P/E of N/A (forward -95.0). TrendMatrix value score: 5.7/10. Verdict: Sell.
17 analysts cover NUVB with a consensus score of 4.1/5. Average price target: $12.
What does Nuvation Bio Inc. do?Nuvation Bio is a global oncology company that commercially launched IBTROZI (taletrectinib), a ROS1 inhibitor for...
Nuvation Bio is a global oncology company that commercially launched IBTROZI (taletrectinib), a ROS1 inhibitor for metastatic non-small cell lung cancer, in the U.S. in June 2025 following FDA approval, with taletrectinib also approved in Japan (marketed by partner Nippon Kayaku) and China (marketed by partner Innovent Biologics). IBTROZI is the company's only FDA-approved product and its near-term revenue depends on its U.S. commercial launch, while Nuvation's pipeline also includes safusidenib, an oral mIDH1 inhibitor in Phase 3 development, with both drugs originally licensed from Daiichi S